Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D McLain

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Journal of Cancer Research and Clinical Oncology|October 16, 2001
GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trialM A Hussein, K Sandstrom, P Elson, et al.
Journal of Cancer Research and Clinical Oncology|May 18, 2001
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinomaT Olencki, D Peereboom, L Wood, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
A phase I trial of intrapleural recombinant human interferon alpha (rHuIFN alpha 2b) in patients with malignant pleural effusionsA Bhatia, T W Rice, D McLain, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 23, 2000
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effectsT Olencki, J Finke, R Tubbs, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2000
A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancerR Pelley, R Ganapathi, L Wood, et al.
Cancer|March 15, 1996
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinomaE Wos, T Olencki, L Tuason, et al.
Investigational New Drugs|May 1, 1993
Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinomaR M Bukowski, J Young, G Goodman, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase I study of WR-2721 and carboplatinG T Budd, R Ganapathi, L Bauer, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1994
Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effectsR M Bukowski, S A Murthy, J Finke, et al.
Human Molecular Genetics|February 1, 1995
Three new point mutations in type II procollagen (COL2A1) and identification of a fourth family with the COL2A1 Arg519-->Cys base substitution using conformation sensitive gel electrophoresisC J Williams, M Rock, E Considine, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Journal of Cancer Research and Clinical Oncology|October 16, 2001
GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trialM A Hussein, K Sandstrom, P Elson, et al.
Journal of Cancer Research and Clinical Oncology|May 18, 2001
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinomaT Olencki, D Peereboom, L Wood, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1994
A phase I trial of intrapleural recombinant human interferon alpha (rHuIFN alpha 2b) in patients with malignant pleural effusionsA Bhatia, T W Rice, D McLain, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 23, 2000
Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: clinical and biologic effectsT Olencki, J Finke, R Tubbs, et al.
Cancer Chemotherapy and Pharmacology|October 6, 2000
A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancerR Pelley, R Ganapathi, L Wood, et al.
Cancer|March 15, 1996
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinomaE Wos, T Olencki, L Tuason, et al.
Investigational New Drugs|May 1, 1993
Polyethylene glycol conjugated interleukin-2: clinical and immunologic effects in patients with advanced renal cell carcinomaR M Bukowski, J Young, G Goodman, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Phase I study of WR-2721 and carboplatinG T Budd, R Ganapathi, L Bauer, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1994
Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effectsR M Bukowski, S A Murthy, J Finke, et al.
Human Molecular Genetics|February 1, 1995
Three new point mutations in type II procollagen (COL2A1) and identification of a fourth family with the COL2A1 Arg519-->Cys base substitution using conformation sensitive gel electrophoresisC J Williams, M Rock, E Considine, et al.
Pageof 6